Pricing Log in Create free account

IMMURON (IMRN) vs VistaGen Therapeutics, Inc. (VTGN)

IMMURON and VistaGen Therapeutics, Inc. are both Biotechnology companies. IMMURON and VistaGen Therapeutics, Inc. are of similar size ($7.3M and $6.9M). VistaGen Therapeutics, Inc. grew revenue faster over the last twelve months: 287.2% against −6.62%. IMMURON has the higher net margin (−262.7% vs −2,703.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, IMMURON leads on 10 and VistaGen Therapeutics, Inc. on 5.

Valuation

Metric IMRN VTGN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 2.92 9.40
P/B n/m 0.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.93 0.23 0.66
EV/Sales (3.47) (6.44) 9.02
Earnings yield (2.51%) (976.47%) (32.88%)
Free cash flow yield 0.00% (854.68%) (23.13%)

Profitability

Metric IMRN VTGN Biotechnology median
Gross margin 71.28% 100.00% 68.51%
Operating margin 0.00% (2,785.69%) 0.00%
Net margin (262.71%) (2,703.72%) 0.00%
Free cash flow margin 0.00% (2,490.88%) 0.00%
Return on equity 0.00% (166.46%) (51.96%)
Return on assets 0.00% (129.22%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMRN VTGN Biotechnology median
Revenue growth (TTM) (6.62%) 287.15% 6.76%
EPS growth (last fiscal year) 37.29% (9.58%) 29.88%
Revenue growth, 5-year CAGR 116.96% 3.10% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMRN VTGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.26 3.07 4.97
Net debt to EBITDA 1.81 0.63 1.01

Dividend

Metric IMRN VTGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMRN VTGN Biotechnology median
Market cap 6.86m 7.33m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack